Table 3.
People who talked about trastuzumab
| Pre‐specified actor category | n/218 | Percentage (95% CI) |
|---|---|---|
| Individual with history of breast cancer or their family member | 104 | 47.7 (41.1–54.3) |
| PCT | 35 | 16.1 (11.2–20.9) |
| Politician | 33 | 15.1 (10.4–19.9) |
| Charity/pressure group | 24 | 11.0 (6.9–15.2) |
| Oncologist/‘breast specialist’ | 17 | 7.8 (4.2–11.4) |
| Journal/journal editor | 10 | 4.6 (1.8–7.4) |
| Department of Health | 9 | 4.1 (1.5–6.8) |
| Roche (manufacturer) | 7 | 3.2 (0.9–5.6) |
| NICE | 1 | 0.5 (−0.4–1.4) |
| Other categories | 41 | 18.8 (13.6–24) |
| Legal profession (lawyer, solicitor, judge) | 24 | 11 (6.9–15.2) |
| Unspecified ‘specialists’ or ‘experts’ or ‘scientists’ | 5 | 2.3 (0.3–4.3) |
| Private insurer | 3 | 1.4 (−0.2–2.9) |
| Nurse (non‐patient) | 2 | 0.9 (−0.3–2.2) |
| Health economist | 2 | 0.9 (−0.3–2.2) |
| Celebrity (including royal) | 1 | 0.5 (−0.4–1.4) |
| Financial services | 1 | 0.5 (−0.4–1.4) |
| Scottish medicines consortium | 1 | 0.5 (−0.4–1.4) |
| Trade union representative | 1 | 0.5 (−0.4–1.4) |
| Acute trust spokesperson | 1 | 0.5 (−0.4–1.4) |
| EMEA | 1 | 0.5 (−0.4–1.4) |
| No source | 72 | 33 (26.8–39.3) |
NICE, National Institute for Health and Clinical Excellence; PCT, primary care trust; EMEA, European Medicines Agency.